Daniel John Finnemore

Title: The Innovations of Daniel John Finnemore

Introduction

Daniel John Finnemore is a notable inventor based in Oxfordshire, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for phosphoinositide 3-kinase. With a total of two patents to his name, Finnemore's work is recognized for its potential therapeutic applications.

Latest Patents

Finnemore's latest patents include innovative tricyclic heterocyclic compounds designed as phosphoinositide 3-kinase inhibitors. The first patent describes a compound of formula I or a pharmaceutically acceptable salt thereof and/or stereoisomers thereof, emphasizing its utility in therapy. The second patent also focuses on tricyclic heterocyclic compounds, detailing a compound of formula I, where each R is independently selected from various chemical groups, with the stipulation that at least one of the R groups is not hydrogen.

Career Highlights

Finnemore is currently associated with Karus Therapeutics Limited, a company dedicated to advancing therapeutic solutions. His work at Karus Therapeutics has positioned him as a key player in the pharmaceutical industry, contributing to the development of innovative treatments.

Collaborations

Throughout his career, Finnemore has collaborated with esteemed colleagues such as Stephen Joseph Shuttleworth and Franck Alexandre Silva. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.

Conclusion

Daniel John Finnemore's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in therapeutic solutions.